AMD

The biosimilar to aflibercept (Eylea) had already received approval in the EU and US.

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria.

Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.

The topline results from the COAST trial is anticipated in early Q2 of 2025.

At the Envision Summit 2025 in San Juan, Puerto Rico, Giulia Corradetti, MD discussed AI applications in the identification and prediction of OCT structural biomarkers in intermediate AMD.

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

AVT06 is Alvotech’s proposed biosimilar to Eylea (aflibercept) 2mg.

Examining the performance of AI algorithms versus human graders in neovascular age-related macular degeneration

At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid outcomes analysis of patients who participated in the phase 3 clinical trial PULSAR.

How modern tools may lead to customized AMD treatment plans

Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.

Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining clinical trial protocols’ stringent adherence and monitoring in everyday practice.

Researchers screened for outcomes such as the presence of retinal diseases including age-related macular degeneration and retinal vein occlusion

David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial.

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration.

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial.

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.

The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery

Patients commonly reported unexplained blurred or hazy vision postoperatively that requires further investigation

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after 6 months of treatment in a retrospective chart review that included 102 patients with nAMD who had had suboptimal responses to other anti-VEGF therapies.

The data will be presented virtually at Angiogenesis, Exudation, and Degeneration 2025 on February 8 and February 10, 2025.